Trials Sponsors Conditions Drugs Pricing

Conditions

Overweight and Obesity Insulin Resistance

Outcome Measures

Primary Outcomes (1)

Carotid Femoral Pulse Wave Velocity
cfPWV is the gold standard of arterial stiffness. It was assessd during experimental visits, under the same conditions in a blinded manner
baseline, 3 and 6 mo

Other Outcomes (3)

Systolic Blood Pressure
3 and 6 mo
Brachial Artery Flow Mediated Dilation (FMD)
Baseline, 3 months (interim) and 6 months (final)
Popliteal Artery Flow Mediated Dilation (FMD)
Baseline, 3 months (interim) and 6 months (final)

Study Arms (2)

Placebo

PLACEBO COMPARATOR

6 months of daily placebo

Drug: Placebo - Cap

Amiloride

EXPERIMENTAL

6 months of amiloride (max dose 5 mg) treatment

Drug: Amiloride Pill

Interventions

Placebo - CapDrug

6 months of 1 pill a day

Placebo

Amiloride PillDrug

Max dose of 5 mg a day for 6 months

Amiloride

Eligibility Criteria

Age30 Years - 70 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

to 70 years of age at randomization
Body mass index (BMI) 25.1-50 kg/m2 or waist circumference \> 88 cm (\> 35 in) in women and \>102 cm (\>40 in) in men. 3, 4

Sponsors & Collaborators

University of Missouri-Columbia
Otherlead

Study Sites (1)

University of Missouri Hospital and Clinics

Columbia, Missouri, 65201, United States

MeSH Terms

Conditions

OverweightObesityInsulin Resistance

Interventions

Amiloride

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Intervention Hierarchy (Ancestors)

Results Point of Contact

Title: Camila Manrique, MD
Organization: University of Missouri

Study Officials

Camila Manrique Acevedo, MD
University of Missouri-Columbia
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: No
Restrictive Agreement: No

Enrollment

137 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2 3
Allocation: RANDOMIZED
Masking: TRIPLE
Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor, Endocrinology

Study Record Dates

First Submitted

February 8, 2019

First Posted

February 12, 2019

Study Start

July 15, 2019

Actual (reported)

ENAC Blockade and Arterial Stiffness

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Other Outcomes (3)

Study Arms (2)

Placebo

Amiloride

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Other Outcomes (3)

Study Arms (2)

Placebo

Amiloride

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations